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Abstract
Background: The successful targeting of neuroblastoma (NB) by associating tumor-initiating cells (TICs) is a major
challenge in the development of new therapeutic strategies. The subfamily of aldehyde dehydrogenases 1 (ALDH1)
isoenzymes, which comprises ALDH1A1, ALDH1A2, and ALDH1A3, is involved in the synthesis of retinoic acid, and
has been identified as functional stem cell markers in diverse cancers. By combining serial neurosphere passages
with gene expression profiling, we have previously identified ALDH1A2 and ALDH1A3 as potential NB TICs markers
in patient-derived xenograft tumors. In this study, we explored the involvement of ALDH1 isoenzymes and the
related ALDH activity in NB aggressive properties.
Methods: ALDH activity and ALDH1A1/A2/A3 expression levels were measured using the ALDEFLUOR™ kit, and by
real-time PCR, respectively. ALDH activity was inhibited using the specific ALDH inhibitor diethylaminobenzaldehyde
(DEAB), and ALDH1A3 gene knock-out was generated through the CRISPR/Cas9 technology.
Results: We first confirmed the enrichment of ALDH1A2 and ALDH1A3 mRNA expression in NB cell lines and
patient-derived xenograft tumors during neurosphere passages. We found that high ALDH1A1 expression was
associated with less aggressive NB tumors and cell lines, and correlated with favorable prognostic factors. In
contrast, we observed that ALDH1A3 was more widely expressed in NB cell lines and was associated with poor
survival and high-risk prognostic factors. We also identified an important ALDH activity in various NB cell lines and
patient-derived xenograft tumors. Specific inhibition of ALDH activity with diethylaminobenzaldehyde (DEAB)
resulted in a strong reduction of NB cell clonogenicity, and TIC self-renewal potential, and partially enhanced NB
cells sensitivity to 4-hydroxycyclophosphamide. Finally, the specific knock-out of ALDH1A3 via CRISPR/Cas9 gene
editing reduced NB cell clonogenicity, and mediated a cell type-dependent inhibition of TIC self-renewal properties.
Conclusions: Together our data uncover the participation of ALDH enzymatic activity in the aggressive properties
and 4-hydroxycyclophosphamide resistance of NB, and show that the specific ALDH1A3 isoenzyme increases the
aggressive capacities of a subset of NB cells.
Background
Neuroblastoma (NB), which arises from neural crest-
derived sympatho-adrenal progenitors, is one of the
most life-threatening solid tumors of childhood [1–3].
The hallmark of NB is its extreme biological, genetic,
and clinical heterogeneity. This leads to a broad spectrum
of clinical outcomes, ranging from spontaneous regression
to an aggressive life-threatening disease for high-risk NB,
with only 40 % long-term survival despite intensive multi-
modal therapy [1–3]. While only few recurrent gene
mutations have been found in NB tumors, a large number
of recurrent somatic genetic alterations have been
described, which includes numerical or segmental
chromosomal alterations [1, 2, 4–6].
Like their tumor of origin, NB cell lines display
important biological heterogeneity. Three cell subtypes
arise spontaneously in NB cell line cultures: a) neuro-
blastic (N-type), displaying properties of embryonic
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sympathoblasts, b) substrate-adherent (S-type), resem-
bling Schwannian, glial or melanocytic progenitor cells,
and c) intermediate (I-type) subtype [7]. I-type cells
express markers of both N and S subtypes and display
bidirectional differentiation potential when treated with
specific agents [8–10]. Moreover, I-type cells are signifi-
cantly more aggressive than N- or S-type cells, and were
proposed to represent NB stem cells (SCs) or malignant
neural crest SCs [9, 11].
In recent years, emerging evidence has suggested that
tumor progression, metastasis, and chemotherapeutic
drug resistance are driven by a minor cell subpopulation,
designed as cancer stem cells (CSCs) or tumor-initiating
cells (TICs) [12–14]. These are capable of self-renewal
and differentiation into heterogeneous phenotypic and
functional lineages, and are characterized by plasticity
[14–16]. In a previous study aiming to identify NB TIC
markers, we combined serial neurosphere (NS) passage
assays, which allow the enrichment of TICs, with gene
expression profiling. This allowed the identification of a
gene expression signature associated to NB TICs [17].
Among this gene profile, ALDH1A2 and ALDH1A3
were selected for further investigations of their role in
maintaining NB TIC properties. The rationale behind
this selection is based on the demonstration of the im-
plication of ALDH activity in the biology of normal SCs
and CSCs in other settings [18–21].
ALDHs belong to a superfamily of 19 genes coding for
NAD(P)+-dependent enzymes involved in the detoxifica-
tion of a large number of endogenous and exogenous
aldehydes [22, 23]. The ALDH1 subfamily, which includes
A1, A2 and A3 isoforms, is involved in the synthesis of
retinoic acid, playing therefore an important role in devel-
oping tissues [22]. Elevated ALDH activity was first
demonstrated in normal hematopoietic progenitor/stem
cells and is now commonly used for the isolation of CSCs
in multiple tumor settings [24, 25]. Moreover, several
ALDH isoenzymes were associated to TICs properties,
such as ALDH1A1 in melanoma and lung adenocarcin-
oma [20, 26], ALDH1B1 in colon cancer [27], ALDH1A3
in breast cancer and NSCLC [28, 29], and ALDH7A1 in
prostate cancer [30]. ALDH1 expression was also
correlates with cyclophosphamide resistance [23, 31, 32], a
chemotherapeutic drug widely used for the treatment of
many cancers, including NB. So far, ALDH activity has
not been linked to NB tumor initiation or progression.
However, a recent paper described the involvement of
ALDH1A2 in the regulation of CSC properties in NB [33].
In this study, we aimed at exploring the expression
pattern of the three ALDH1 isoforms in NB cell lines
and patient-derived xenograft (PDX) tumors. ALDH
activity was found to play a role in NB cell aggressive
properties, such as clonogenicity, TIC proliferation, and
cyclophosphamide resistance. In addition, we revealed
that ALDH1A3 is associated with poor prognosis, and
ALDH1A3 gene disruption negatively impacted the
aggressiveness of a subset of NB cell lines, suggesting
that it can enhance NB tumorigenic properties.
Methods
Ethics statement
All in vivo procedures were performed under the guide-
lines of the Swiss Animal Protection Ordinance and the
Animal Experimentation Ordinance of the Swiss Federal
Veterinary Office (FVO). Animal experimentation proto-
cols were approved by the Swiss FVO (authorization
number: 1564.6). All reasonable efforts were made to
ameliorate suffering, including anesthesia for painful
procedures.
Patient-derived xenograft
Tumor material was collected from NB patients, diag-
nosed in the Hemato-Oncology Unit of the University
Hospital of Lausanne (Switzerland), after informed
consent and in agreement with local institutional ethical
regulations (Protocol 26/05, 07/02/2005). Patient-derived
xenografts (PDX) NB1, NB2 and NB4 were produced by
in vivo serial subcutaneous transplantations of bone-
marrow derived tumor cells in athymic Swiss nude mice
(Crl:NU(Ico)-Foxn1nu) from Charles River Laboratory
(France) [17]. PDX tumors were dissociated as
previously described [17].
Cell culture
All well-characterized NB cell lines [34–36] were grown
in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco,
Paisley, UK) supplemented with 10 % Fetal Bovine
Serum (FBS) (Sigma-Aldrich, St Louis, USA) and 1 %
penicillin/streptomycin (Gibco). The NB1-C cell line
[17] was established from the dissociated NB1 PDX
tumor derived from bone marrow metastatic cells (stage
4, NMYC not amplified). NB1-C cells were maintained
in Neural Basic Medium (NBM) [DMEM/F12 supple-
mented with 1 % penicillin/streptomycin, 2 % B27
(Invitrogen, Carlsbad, USA), 20 ng/ml human recombin-
ant bFGF (Peprotech, Rocky Hill, USA), and 20 ng/ml
EGF (Peprotech)].
RNA extraction, reverse transcription, and PCR
Total RNAs from NB cells (1 × 106 cells) was obtained
using the RNeasy Mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. RNAs (0.2-
1 μg) were reverse transcribed with the PrimeScriptTM
RT reagent Kit (TAKARA Bio, St.Germain-en-Laye,
France) using random primers and oligo dT primers
according to the manufacturer’s instructions.
The expression levels of ALDH1A1, ALDH1A2,
ALDH1A3, and MYC mRNAs were measured by real-
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time PCR using specific primers (QuantiTect primer
assay, Qiagen), QuantiFast SYBRgreen assay (Qiagen),
and the Corbett Rotor-Gene 6000 real-time cycler (Qia-
gen), as previously described [37]. The cycling condi-
tions comprised 3 min polymerase activation at 95 °C,
followed by 40 cycles of 3 s at 95 °C, 20s at 60 °C and
1 s at 72 °C for fluorescence acquisition. The ratio of
each gene of interest to HPRT1 gene expression and the
relative gene expression were evaluated using the ΔCt
and ΔΔCt methods, respectively.
NANOG, SOX2, and MYC expression levels were ana-
lyzed by PCR using GoTaq Hot Start Kit (Promega,
Madison, USA) with the following primers: NANOG-for
5’-CAGCCCCGATTCTTCCACCAGTCCC-3’, NANOG-
rev 5’-CGGAAGATTCCCAGTCGGGTTCACC-3’, SOX
2-for 5’GGGAAATGGGAGGGGTGCAAAAGAGG-3,
SOX2-rev 5’-TTGCGTGAGTGTGGATGGGATTGGT
G-3’, MYC-for 5’-GCGTCCTGGGAAGGGAGATCCGG
AGC-3’, MYC-rev 5’-TTGAGGGGCATCGTCGCGGG
AGGCTG-3’. Cycling reactions were 2 min at 95 °C
followed by 35 cycles of 30s at 95 °C, 30s at 60 °C and
30s at 72 °C, and 5 min at 72 °C.
ALDEFLUOR assay
ALDH activity was analyzed using the ALDEFLUOR™ kit
according to manufacturer’s instructions (Stem Cell
Technologies, Grenoble, France). Briefly, 1×106 NB cells
or PDX-dissociated cells were resuspended in 1 ml
ALDEFLUOR assay buffer. The ALDH substrate BOD-
IPY™-aminoacetaldehyde (BAAA) was added to the cells.
Immediately after mixing, half of the suspension was
used as the negative control, by adding 5 μl of the
ALDH inhibitor diethylaminobenzaldehyde (DEAB,
3 μM). Cells were incubated for 30–45 minutes at 37 °C,
then washed twice, and suspended in ALDEFLUOR™
assay buffer containing 1 μg/ml of DAPI (Life Technologies,
Switzerland) for viable cells selection. The brightly fluores-
cent ALDH+ cells were detected in the FL1-channel of a
GalliosTM Flow Cytometer (Beckman Coulter, Inc., USA)
and data were analyzed using KALUZA™ software
(Beckman Coulter, Inc., USA).
ALDH activity inhibition
Cells were pre-treated with DEAB (Sigma-Aldrich) at 50
or 100 μM according to the cell line tested, or for control
cells with Dimethyl sulfoxide (DMSO, Sigma-Aldrich) for
3 days prior functional assays, while maintaining the same
amount of DEAB or DMSO during the assay.
Proliferation assay
Cell proliferation was assessed using the MTS/PMS cell
proliferation kit (Promega). Briefly, 104 SK-N-Be2c cells
and 2*104 NB1-C cells per well were seeded in a
96-wells plate in DMEM/FCS or in NBM, respectively.
Proliferation was monitored by measuring the OD at
405 nm immediately after seeding and after 24, 48, 72
and 96 h in presence of DEAB or DMSO for ALDH
inhibition experiments, or without treatment.
Methylcellulose clonogenic assay
Clonogenic assays in semi-solid conditions were
performed as described [38]. Briefly, NB cells (1*103)
were grown in 500 μl semi-solid medium containing
53 % methylcellulose (Fluka), and 47 % DMEM/FCS (for
SK-N-Be2c) or 47 % NBM (for NB1-C) in poly-Hema
(poly2-hydroxyethyl methylacrylate, 16 mg/ml in EtOH;
Sigma-Aldrich) -coated 24-wells plates. For ALDH activ-
ity inhibition assay, DEAB or DMSO was added in the
semi-solid medium, and supplemented every 4 days in
100 μl of medium. After 2 weeks, colonies were counted
using an optic microscope (Olympus, Volketswil,
Switzerland).
NB neurosphere culture and self-renewal assay
NS culture was performed as described in neural crest
stem cell medium (NCSCm) in poly-Hema-coated six
wells plates to prevent cell adhesion [17, 39]. For the
production of serial NS passages, NB cells (1×105 cells/ml)
were plated, and spheres were dissociated every 7 days in
0.05 % trypsin-EDTA (Invitrogen), subsequently inhibited
with Trypsin inhibitor (v/v) (Sigma-Aldrich). At each
sphere passage, a part of the dissociated cells were tested
for ALDH activity and for ALDH1A1/2/3 mRNA expres-
sion. For self-renewal assay, 1×104 cells were plated in
500 μl NCSCm in triplicates without treatment, or in
presence of DEAB or DMSO for ALDH inhibition
experiments.
Cell viability assays
Cells (2×104 for SK-N-Be2c, IGR-N91 and IGR-N91R, or
4*104 for NB1-C) were plated in 96-wells plates 24 h
before treatment with 4-hydroxycyclophosphamide (4-
HCPA, Niomech, Bielefeld, Germany) for 48 h. Cell
viability was measured in quadruplicates using the MTS/
PMS cell proliferation kit from Promega according to
manufacturer’s instructions as described [40].
ALDH1A3 knock out through CRISPR/Cas9 technology
Two sgRNAs targeting the early exon of the ALDH1A3
gene were chosen in the published sgRNA library [41].
Oligos were designed as follow: sgALDH1A3.1:
forward 5’-CACCGCTACATGTAACCCTTCAACT-3’,
reverse 5’-AAACAGTTGAAGGGTTACATGTAGC-3’,
sgALDH1A3.2: forward 5’- CACCGCGCTCAGCCCG
ACGTGGACA-3’, reverse 5’- AAACTGTCCACGTCG
GGCTGAGCGC-3’. The lentiviral vector lentiCRISPR
v2 [42] was obtained from Adgene (Cambridge, USA).
LentiCRISPR v2-sgALDH1A3 plasmids were constructed
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according to the manufacturer’s instructions (Adgene).
Virus production and lentiviral infections were performed
as previously described [43] with the following modifica-
tion: pCMVDR8.91 was replaced by psPAX2 (Adgene).
Transduced SK-N-Be2c and NB1-C cells were selected
24 h post-infection with 5 μg/ml or 1 μg/ml of puromycin
(Sigma-Aldrich), respectively. Control cells were trans-
duced with virus containing the empty lentiCRIPR v2
vector. Clone isolation was performed by limiting dilution
in 96-wells plate.
Validation of the ALDH1A3 KO by immunoblotting
could not be performed due to the detection (using 3
different anti-ALDH1A3 antibodies) of a non-specific
band migrating with a similar velocity as ALDH1A3 in
the negative control SH-EP cell line lacking ALDH1A3
mRNA expression. Thus, genome editing in clones was
verified by NGS sequencing. PCR amplicons were
designed across the ALDH1A3 genomic regions targeted
by the sgRNAs to examine generation of indels. A
second PCR was performed to attach Illumina adaptors
and barcodes to samples according to manufacturer’s
instructions. Primers for the second PCR include both a
variable length sequence to increase library complexity
and an 8 bp barcode for multiplexing of different
biological samples. Amplicons were gel extracted,
quantified, mixed and sequenced with a MiSeq SR300
(Illumina Inc., San Diego, USA). Sequencing reads were
then processed with the following bioinformatic tools to
quantify the occurrence of indels in the selected clones.
Universal Illumina adapter and quality trimming of the
sequencing reads was achieved using Cutadapt [44]. The
trimmed reads were then aligned to the human refer-
ence genome (build GRCh37) using bwa [45] and then
visualized using Integrative Genomics Viewer (IGV,
Broad Institute). In parallel, to quantify the exact
number of genetic variants for each CRISPR clone, we
developed an R script that quantifies the percentage of
each detected variant.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 5.04 (GraphPad Software, Inc., La Jolla, USA).
Unpaired two-tailed parametric t-test or non parametric
Mann Whitney test were carried out to compare two
different conditions, as specified in the Figure Legends.
Results
ALDH1A2 and ALDH1A3 expression are enhanced in NB
TICs
We have previously identified ALDH1A2 and ALDH1A3
genes as potential NB TIC markers as their expression
was upregulated during NS selection of NB TICs derived
from NB PDX tumors (181x and 9x baseline, respect-
ively by Affymetrix microarray analysis) [17]. To confirm
the enrichment in stem-like cells by serial NS passages
of NB cell lines, the expression levels of various SC-
associated markers were analyzed by RT-PCR and real--
time PCR at different sphere passages in the SK-N-Be2c
and NB1-C cell lines. NANOG, SOX2, and MYC mRNA
expression levels were already increased at the second
sphere passage (Additional file 1: Figure S1), confirming
the rapid enrichment of NB TICs through serial NS
culture.
To validate the prior microarray data and to provide a
closer insight into ALDH1 isoenzyme expression status
along the NB TIC selection, we analyzed the mRNA
expression levels of the three ALDH1 isoforms in four
successive NS passages and in parental cells (T0) grow-
ing in adherent conditions (Fig. 1). ALDH1A1 mRNA
expression levels during TIC selection varied depending
on the cell type and NS passages analyzed. In contrast,
ALDH1A2 mRNA expression was strongly increased, in
early steps of the TIC selection process (s1-s2) and
remained elevated in later NS passages (s3-s4) in the
I-type SK-N-Be2c cell line, as well as in the NB1 PDX
tumor and the related NB1-C cell line (Fig. 1). Moreover,
ALDH1A3 mRNA expression was also highly upregu-
lated in the NB1 PDX tumor and in the SK-N-Be2c cell
line during TIC selection, while it remained stable in the
NB1-C cell line (Fig. 1). Altogether, these results confirm
the enrichment of ALDH1A2 and ALDH1A3 mRNA
expression observed in the NS microarray profiling
derived from the NB PDX tumors [17].
ALDH activity was also measured during successive
NS passages from T0 to NS passage 4 (s4) in the SK-N-
Be2c and NB1-C cell lines, and in cells derived from the
NB1 PDX. The percentage of ALDH+ cells remained
stable during TIC selection in all cells analyzed; simi-
larly, the relative fluorescence intensity remained more
or less constant during NS passages except for a slight
increase in the NB1-C cell line (Fig. 2a and b). These
results indicate a lack of correlation between ALDH
activity (as measured using the ALDEFLUOR kit) and
ALDH1 isoform expression in NB TICs (see Discussion).
NB cell lines and PDX tumors display cell-specific ALDH1
isoenzyme expression profiles and elevated ALDH activity
Next, the expression profile of each ALDH1 isoform was
evaluated by real-time PCR in a large panel of NB cell
lines and NB PDX tumors. Most NB cell lines analyzed
expressed ALDH1A1 and/or ALDH1A3, but rarely
ALDH1A2 (Fig. 3a). The less aggressive S-type cell lines
expressed significantly higher levels of ALDH1A1
mRNA relative to N/I-type NB cells (Fig. 3a and b).
Interestingly, the NB1-C cell line and the related NB1-
PDX tumor displayed a similar expression pattern of
ALDH1 isoenzymes, with elevated expression levels of
ALDH1A1 and A3. Furthermore, the expression level of
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ALDH1A3 was significantly enhanced in the three PDX
tumors as compared to NB cell lines, suggesting a role of
this isoenzyme in in vivo grown tumors (Fig. 3a and b).
Further analysis of ALDH activity revealed elevated,
yet heterogeneous, percentages of ALDH+ cells in NB
cell lines and PDX tumors, ranging from 1.2 to 69 %
(Fig. 4a and b).
High ALDH1A3 expression in NB tumors correlates with
poor outcome and high-risk prognostic markers
To identify the link between ALDH1 expression and NB
aggressiveness, the ALDH1A1/A2/A3 expression patterns
were analyzed in NB tumors using the R2: Genomics
Analysis and Visualization Platform (http://r2.amc.nl).
Analysis of the published dataset of Versteeg and
colleagues [5] revealed that high ALDH1A1 expression is
significantly associated with good prognosis, while
elevated expression of ALDH1A3 is strongly correlated
with poor survival (Fig. 5a). The expression level of
ALDH1A2 is globally reduced in NB tumors compared to
ALDH1A1 and A3 isoforms, but the rare tumors with
high ALDH1A2 expression level displayed a very poor
survival rate (Fig. 5a). Moreover, low expression levels of
ALDH1A1 (Fig. 5b) or high expression levels of
ALDH1A3 (Fig. 5c) are associated with unfavorable
prognostic factors in NB (i.e., age at diagnosis >18 months,
and stage 4 disease).
Inhibition of ALDH activity affects NB aggressive
properties
We next investigated whether the inhibition of ALDH
activity in NB cell lines affects the NB cell properties
associated with aggressiveness, such as proliferation,
anchorage-independent growth, and TIC self-renewal.
First, we confirmed that subtoxic doses of DEAB, a well-
known specific inhibitor of ALDH activity [21], fully
inhibit ALDH activity, which can be recovered by DEAB
removal (Additional file 1: Figure S2). Treatment with
DEAB had no impact on the 2D-proliferation capacities
of SK-N-Be2c and NB1-C cell lines (Fig. 6a). However,
ALDH activity inhibition strongly affected NB cell
clonogenic properties (Fig. 6b), and negatively impacted
on TIC self-renewal capacities of SK-N-Be2c and NB1-C
cell lines by 43 and 88 %, respectively (Fig. 6c).
As ALDH activity was shown to mediate resistance to
4-hydroxycyclophosphamide (4-HCPA), NB cell sensitiv-
ity to this chemotherapeutic agent was also measured in
presence or absence of DEAB. We observed that ALDH
inhibition partly sensitized SK-N-Be2c and NB1-C cell
lines to 4-HPCA (Fig. 6d). In addition, we analyzed two
cell lines, the drug-sensitive IGR-N91, and the multidrug
resistant IGR-N91R, previously established in our lab
[35]. Interestingly, ALDH enzymatic inhibition was able
to almost completely sensitize the IGR-N91 cells to
4-HCPA and had a strong sensitizing impact on the
multidrug resistant IGR-N91R cells (Fig. 6e). Altogether
Fig. 1 ALDH1A2 and A3 isoform expression are enhanced during NB self-renewal process. The mRNA expression levels of the three ALDH1
isoforms (ALDH1A1, ALDH1A2 and ALDH1A3) were analyzed by real-time PCR in parental cells (T0) and four sphere passages (s1 to s4) of
SK-N-Be2c, NB1-C, and NB1 PDX-derived cells. Data are plotted as ALDH1 mRNA expression relative to the T0 parental cells in pooled s1-s2 and
s3-s4 ± SD (unpaired t-test: * correspond to p < 0.05, ** p < 0.01, *** p < 0.0001)
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these results demonstrate that endogenous ALDH activ-
ity plays a role in NB cell aggressive properties and me-
diates NB cell resistance to the chemotherapeutic drug
4-HCPA.
ALDH1A3 knock out affects NB clonogenic properties
Although ALDH activity measured by the ALDEFLUOR
assay was initially mainly attributed to the ALDH1A1
isoform, other ALDH isoenzymes, such as ALDH1A2,
ALDH1A3, ALDH2, ALDH3A1, and ALDH9A1, could
be involved in the measured ALDH activity [21, 25, 28,
29]. As the ALDH1A3 isoform is associated with poor
survival in NB and is the most widely expressed ALDH1
isoform in our panel of NB cell lines and PDX tumors
(Figs. 5a and 3a, respectively), we asked whether
ALDH1A3 activity plays a functional role in NB aggres-
sive phenotype. To answer this question, ALDH1A3
knock-out (KO) SK-N-Be2c and NB1-C cell lines were
generated by CRISPR/Cas9 gene editing (Additional file
1: Figure S3). Similarly, as for the observations after
DEAB-mediated ALDH inhibition, ALDH1A3 KO did
not affect the 2D-cell proliferation properties, but de-
creased the 3D-anchorage-independent growth of both
NB cell lines (Fig. 7a and b). While, ALDH1A3 KO only
impaired the TIC self-renewal properties of the SK-N-
Be2c cell line, but had no effect on NB1-C cells (Fig. 7c).
Discussion
In this study, we first confirmed the enrichment of
ALDH1A2 and ALDH1A3 expression during NB TICs
Fig. 2 ALDH activity remains stable during NB TICs selection. ALDH activity was measured using the ALDEFLUOR kit in parental cells (T0) and
successive sphere passages (s1 to s4) in SK-N-Be2c, NB1-C, and NB1 PDX-derived cells. a The percentage of ALDH+ cells (black bars) and the mean
fluorescence intensity (MFI) ratio (MFI of the test tube/control tube, red bars) are plotted as mean ± SD of more than 3 experiments according to
cell availability at each sphere passage (unpaired t-tests: ***p < 0.0005). b Representative dot plots showing the ALDH activity in SK-N-Be2c and
NB1-C parental cells (T0) and in sphere passages 4 (s4) in presence (control tube) or absence (test tube) of DEAB. The percentage of ALDH+ cells
are indicated in the dot plots
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selection in one PDX tumor (NB1), as well as in two dis-
tinct cell lines, the NB1-C cells derived from the NB1
PDX tumor, and/or the I-type SK-N-Be2c cell line. The
enhancement of ALDH1A2 and ALDH1A3 mRNA ex-
pression levels during TIC selection of NB1-PDX derived
cells was in accordance with the fold increase (181x and
9x, respectively) as observed in our previous microarray
analysis [17]. Interestingly, the implication of ALDH1A2
in the regulation of CSC properties in NB has recently
been reported [33]. Moreover, high ALDH1A2 expression
in NB correlates with poor survival, suggesting a role for
this ALDH1 isoenzyme in NB tumor aggressiveness.
ALDH activity has been demonstrated to select CSCs
in leukemia and breast, lung, liver, prostate, brain, and
colon cancer [23–25]. However, despite significant over-
expression of ALDH1A2 and ALDH1A3 during TIC
selection, no increase in the percentage of ALDH+ cells
could be observed during NS-passages by ALDEFLUOR
assay measurements. This suggests that ALDH enzym-
atic activity may not be a valuable functional marker of
TICs in NB. Similar findings were previously described
in melanoma [46].
Our analysis of ALDH1 isoform expression profiles in
NB cell lines and PDX tumors revealed differential
Fig. 3 NB cell lines and PDX tumors display various ALDH isoenzyme expression patterns. a Basal endogenous mRNA expression levels of each
ALDH1 isoform were measured in 10 NB cell lines (* = serum-free medium) and 3 NB PDX tumors by real-time PCR. Mean ratio of ALDH1 isoform/
HPRT1 ± SD are plotted in the bar graphs. Experiments were performed in tri- or quadruplicates (nd: not detected). b Comparison of ALDH1A1/
A2/A3 mRNA expression levels between S-type versus N/I-type cell lines (left panel) and NB cell lines versus PDX tumors (right panel). Individual
values and mean values ± SD of ALDH1 isoform/HPRT1 ratio are plotted in the dot plots (Mann Whithney test *p = 0.033, **p = 0.007)
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expression patterns which may rely on the strong het-
erogeneity of NB tumors and cell lines. The higher
expression levels of ALDH1A1 in the less aggressive
S-type cell lines is in accordance with the finding that
elevated ALDH1A1 expression in NB tumors correlates
with a better survival rate and favorable prognostic
factors. In other neoplasms, ALDH1A1 has been shown
to correlate either with favorable or poor prognosis
depending on the tumor setting or on tumor sample sets
[23]. Moreover, we observed that ALDH1A3 is strongly
expressed in PDX tumors, and that higher ALDH1A3
expression correlates with poor survival and high-risk
Fig. 4 Heterogeneous ALDH activity is detected in NB cell lines and PDX tumors. a The percentage of ALDH+ cells (black bars) and the MFI ratio
(MFI of the test tube/control tube, red bars), measured using the ALDEFLUOR kit, are given as mean ± SD of 1 to 8 experiments for the NB cell
lines and 3 to 4 experiments for the PDX-dissociated tumor cells. b Representative dot plots showing the ALDH activity in SK-N-Be2c, NB1-C cell
lines, and cells dissociated from the 3 PDX tumors in presence (control tube) or absence of DEAB (test tube). The percentages of ALDH+ cells
are indicated
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prognostic markers. These observations, as well as the
ALDH1A3 enrichment in NB TICs, suggest that
ALDH1A3 isoenzyme could be linked to NB progression
and aggressiveness. This correlates with other studies
showing that high ALDH1A3 expression is associated
with more aggressive forms of breast, glioblastoma,
glioma, and pancreatic cancer [28, 47–49].
NB PDX tumors and cell lines also displayed a strong
and heterogeneous ALDH enzymatic activity. However,
no correlation between the expression levels of a specific
ALDH1 isoform and ALDH activity could be identified
in these samples, as well as during NB TIC selection.
Although the ALDH enzymatic activity measured by the
ALDEFLUOR kit was initially mainly attributed to
ALDH1A1, other ALDH isoenzymes were also involved
[21, 25, 28, 29]. Further investigations are needed to
determine if the ALDH activity detected in NB cells can
be associated with a specific ALDH isoenzyme. Yet, we
observed that ALDH1A3 gene disruption had no major
impact on the ALDH enzymatic activity in SK-N-Be2c
and NB1-C clones (Additional file 1: Figure S4). These
data suggest that ALDH1A3 isoenzyme play a negligible
role in the conversion of the ALDH substrate, BODIPY-
aminoacetaldehyde, to fluorescent BODIPY-aminoacetate
reaction products in NB cells, in contrast to breast cancer
and non-small cell lung carcinoma [28, 29].
Drug resistance is a hallmark of CSCs or TICs and is
considered as a major contributing factor of relapse.
Various mechanisms of chemoresistance have been iden-
tified in CSCs, including ALDH activity [50]. Indeed,
ALDH activity has been associated for a long time with
normal SC and CSC resistance to oxazaphosphorines
Fig. 5 ALDH1A3 expression is associated with unfavorable prognostic markers and reduced survival, while ALDH1A1 expression correlates with
less aggressive NB. a-c Graphs were generated from the Versteeg database (n = 88 NB patients) using the R2: Genomics Analysis and Visualization
Platform (http://r2.amc.nl). a Kaplan Meier overall survival curves. b-c ALDH1A1 (b) and ALDH1A3 (c) mRNA expression levels in NB tumors
according to age≤ or > 18 month at diagnosis (left panels) or with stage 4 versus stage 4 s (right panels)
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such as cyclophosphamide [23, 25, 51–53], a drug com-
monly used during NB patient therapy. A
cyclophosphamide-resistant phenotype in relation with
high ALDH activity has not yet been described in NB. In
this study, we demonstrate a significant sensitization of
NB cell lines to 4-HCPA, the active metabolite of cyclo-
phosphamide, upon ALDH activity inhibition with DEAB,
which represents an original finding. Importantly, the
multidrug resistant IGR-N91R cells could be efficiently
resensitized to 4-HCPA using DEAB. As DEAB was
shown to most potently inhibit ALDH1A1, followed by
ALDH2, ALDH1A2, ALDH1B1, ALDH1A3 and
ALDH5A1 [54], further studies will be required to deter-
mine the specific involvement of individual ALDH isoen-
zyme in ALDH-mediated resistance to 4-HCPA in NB.
Interestingly, we also demonstrate in this present study
that treatments of NB cells with DEAB induced a
significant decrease in their anchorage-independent growth
and TIC self-renewal properties. ALDH1A3 gene disruption
also impaired the clonogenic properties of both cell lines
analyzed. However, ALDH1A3 KO only affected the TIC
self-renewal capacities of the SK-N-Be2c cell line, but not
that of NB1-C cells. This observation correlates with the
lack of enrichment of the ALDH1A3 isoenzyme in the
NB1-C cell line during self-renewal assays, in contrast to
ALDH1A3 enrichment in the SK-N-Be2c cells and the NB1
PDX-derived cells (Fig. 1). This suggests that the ALDH1A3
isoenzyme may not play a major role in TIC self-renewal in
the NB1-C cell line.
The limitations of the present work are partly due to
the difficulty to precisely assess both global ALDH activ-
ity and particular isoform inhibition. This is an issue
shared by all prior reports on ALDH function. In fact,
the ALDEFLUOR kit has been thought to faithfully
Fig. 6 DEAB-mediated ALDH inhibition affects NB aggressive properties and sensitizes NB cells to 4-hydroxycyclophosphamide. Analyses of the
impact of ALDH activity inhibition by DEAB treatment on NB cell proliferation (2D-growth, a), clonogenicity (3D-growth, b), TICs self renewal (c),
and sensitivity to 4-HCPA (a-e). SK-N-Be2c and NB1-C cell lines were pre-treated with 100 or 50 μM of DEAB, respectively, for three days before
starting functional assays performed in presence of DEAB or DMSO as control. a Mean OD at 405 nm± SD of 4 (SK-N-Be2c) or 2 (NB1-C) experiments
performed in quadruplicates. b Mean of relative colony numbers ± SD of 3 experiments performed in duplicates (unpaired t-test *p < 0.05, ***p≤
0.0005). c Mean ratio of cell number/cell plated ± SD of 2 experiments performed in triplicates (unpaired t-test ***p≤ 0.0001). d Cell viability of
SK-N-Be2c and NB1-C cells treated for 48 h with indicated doses of 4-HCPA in presence or absence of DEAB (100 μM and 50 μM, respectively). Mean
values ± SD of 3 experiments performed in quadruplicates (unpaired t-test *p < 0.02, ***p≤ 0.0001). e Cell viability of IGR-N91 and IGR-N91R cells
treated for 48 h with indicated doses of 4-HCPA in presence or absence of DEAB (100 μM). Mean values ± SD of 3 experiments performed in
quadruplicates (unpaired t-test ***p≤ 0.0005)
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measure ALDH1A1 isoform activity, a presumption
which has subsequently been shown not be entirely
correct (see above). Moreover, DEAB selectively inhibits
specific ALDH isoenzymes, and this at various levels of
efficiency. In this study, we addressed these limitations
by performing genetic knock-outs that (from our previ-
ous work on TICs) appeared to influence the biology of
NB, and investigated their impact. Similarly, as for other
metabolic pathways involved in oncogenesis, the func-
tional redundancy of multiple enzymatic isoforms limits
the investigation of the mechanistic underpinnings
behind the effects we and other observed. Nonetheless,
we feel that, while our findings are mostly focused on in
vitro assays for oncogenic potential, this study opens
new avenues for in vivo investigations. In particular, the
ALDH-associated re-sensitization of NB to frequently
used chemotherapeutic agents (i.e., cyclophosphamide)
will need to be further detailed as it constitutes a poten-
tial translational avenue. In addition, the data linking
ALDH variation with clinical outcomes in NB patients
correlate with our prior work and the current results.
We feel they constitute an encouraging step towards
further work addressing the role of ALDH isoforms in
murine models of NB, in particular PDX.
Conclusions
Our results highlight the impact of ALDH enzymatic
activity on the aggressive properties of NB in addition to
Fig. 7 Specific ALDH1A3 KO impairs NB cell clonogenic properties. a-c Impact of ALDH1A3 specific KO was analyzed on the proliferation (a),
clonogenic (b), and TIC self-renewal (c) capacities. a Mean OD at 405 nm ± SD of 3 experiments performed in quadruplicates. b Mean of relative
colony numbers ± SD of 3 experiments performed in duplicates (unpaired t-test *p < 0.05). c Mean ratio of cell number/cell plated ± SD of 3
experiments performed in duplicates in pooled s1 to s3 passages (s1-s3) (unpaired t-test **p≤ 0.005)
Flahaut et al. BMC Cancer  (2016) 16:781 Page 11 of 13
its resistance to 4-HCPA. Further work is needed to
identify the specific ALDH isoenzyme(s) involved as they
may be considered for future therapeutic strategies for
high-risk NB.
Additional file
Additional file 1: Figure S1. Stem cell markers are enriched during
neurosphere culture. Figure S2. DEAB treatment is efficient to transitory
inhibit ALDH activity. Figure S3. Illustration of the insertions/deletions in
the different ALDH1A3 KO clones. Figure S4. ALDH1A3 KO has no
impact on the percentage of ALDH+ cells. (TIF 3370 kb)
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